Researchers at Stanford Engineering University have developed a new technique called Millispinner thrombectomy, which could significantly improve success rates in treating strokes, heart attacks, pulmonary embolisms, and other conditions caused by blood clots. In a paper published on June 4 in Nature, researchers demonstrated through flow models and animal studies that the Millispinner significantly outperforms available treatments and offers a new approach for rapid, simple, and complete removal of blood clots. "In most cases, we more than double the effectiveness of current technology, and even with the most stubborn clots – which we only remove about 11% of the time with current devices – we are able to open the artery on the first try 90% of the time," said co-author Jeremy Heit, head of the Division of Neuroradiology and Neurointervention at Stanford and an associate professor of radiology. "It's incredible. This technology is a game-changer and will...

There was a time when laboratory medicine professionals looked to the future with hope. The year 1996, when the German Medical Fee Schedule (GOÄ) was last comprehensively reformed, is now almost three decades ago. Back then, the world was still analog, mobile phones were bulky luxury items, and laboratory medicine dreamed of a future where its services would finally be adequately valued. However, the current GOÄ amendment, presented with much fanfare in 2025, has once again ignored laboratory medicine. With a wink and a pinch of irony, we shed light on why laboratory medicine professionals may now have to wait until 2055 for a reform – if they are lucky. A déjà vu of ignorance The GOÄ, this venerable set of rules governing fees for medical services, is a bit like a vintage car: charming, but technically outdated. Since 1996, medicine has revolutionized – from the introduction of PCR technology...

The relationship between the United States and Germany is of strategic importance, especially in times of global uncertainty. When U.S. President Donald Trump meets with German Chancellor Friedrich Merz in 2025, a variety of topics will be on the agenda, including trade, defense, and international security. However, one central point overshadows the conversation: Trump's distrust of Merz, based on his failure to fulfill political promises in Germany. This article analyzes the reasons for this distrust, with a particular focus on the key election promises that Merz has not kept, and sheds light on the impact on transatlantic relations. The context of the meeting Donald Trump's second term, which began in 2025, is characterized by a foreign policy line based on bilateralism, economic strength, and clear commitments. Trump has repeatedly emphasized that he expects concrete results from allies, especially from NATO members like Germany. Friedrich Merz, who has been... 

Fresenius Medical Care (FME), the world’s leading provider of products and services for individuals with renal diseases, today begins the second phase of the company’s efforts to introduce high-volume hemodiafiltration (HVHDF) kidney replacement therapy across the United States. The company last week received FDA 510(k) clearance for the updated version of its new, hemodiafiltration-capable 5008X CAREsystem with additional features, a key benchmark enabling the next steps in the company’s broader commercialization efforts across the U.S. later this year, followed by a full-scale commercial launch in 2026. Fresenius Medical Care first received 510(k) clearance for its 5008X CAREsystem in February 2024, which allowed the company to conduct focused testing, clinical evaluations, and user-studies of the device in a pilot clinic. Last week’s May 2025 FDA 510(k) notice provided clearance for an updated 5008X CAREsystem with additional features, including the Fresenius Clinical…